Tarsus Pharmaceuticals price target raised to $72 from $65 at Oppenheimer

Oppenheimer analyst Francois Brisebois raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $72 from $65 and keeps an Outperform rating on the shares. After November showed a solid performance despite the holidays, December impressed even more with IQVIA at 24,031 vs. November’s 20,689 and October’s 20,137, the firm notes. As Tarsus continues to impress, Oppenheimer sees its execution as derisking.